Century Therapeutics (IPSC)
(Delayed Data from NSDQ)
$1.54 USD
+0.08 (5.48%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $1.54 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IPSC 1.54 +0.08(5.48%)
Will IPSC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IPSC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IPSC
Century Therapeutics, Inc. (IPSC) Reports Q2 Loss, Tops Revenue Estimates
Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade
IPSC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Century Therapeutics, Inc. (IPSC) Reports Q1 Loss, Tops Revenue Estimates
Amneal (AMRX) Stock Jumps 7.3%: Will It Continue to Soar?
How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4%
Other News for IPSC
Century Therapeutics price target lowered by $2 at H.C. Wainwright, here's why
Wall Street Analysts Are Bullish on Top Healthcare Picks
Piper Sandler Reaffirms Their Buy Rating on Century Therapeutics (IPSC)
Buy Rating for Century Therapeutics Amidst Shift in Cell Therapy Market and Safety Concerns of Competitors
Analysts Have Conflicting Sentiments on These Healthcare Companies: Cronos Group (CRON), Relay Therapeutics (RLAY) and Century Therapeutics (IPSC)